Thanks for the opportunity, sir and congrats for the great set of numbers. Sir, first, a clarification about the government grants. In fact, in the previous year, we have seen something around Rs. 300-odd crores, in the first half, it is more than Rs. 200 crores that we have already booked. So, what is the visibility here and how long this can sustain and this is relating to the PLI only or something else?
But this is sustainable, sir?
About the US business, m y first question is that is it fair to believe that kind of thing that you would have seen in the Albuterol possibly that has been covered by new launches like Revlimid and all? Is that the understanding right, sir because in terms of the prescription, there is more than 20% kind of decline in Albuterol that we are witnessing?
Since after Revlimid launch, we have crossed that 12 month s period, so generally there was a kind of a term that in the 12 month s period the volume limit means whatever the volume that one need to achieve , that will be based on the 12 month s period achievement. So , from that angle, is it possible to have a sense that okay what is the kind of volume that we would be tracking there in US so far as Revlimid is concerned?